271 unknown. 271 Phase 1, 135 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 271 | Unknown 271 |
| Phase 2 | 135 | Unknown 135 |
Follow Leukemia: new trials by email Literature Review of Leukemia trials Research Report on Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia DFP-10917, Venetoclax - Leukemia, Myeloid, Acute | Phase 1 / Phase 2 | Unknown | Delta-Fly Pharma, Inc. | 39 | 2024-06-12 | 2025-09-03 |
| Natural Killer(NK) Cell Therapy Targeting CLL1 or CD33 in Acute Myeloid Leukemia iPSC-NK cells - AML, Adult | Phase 1 | Unknown | Zhejiang University | 24 | 2024-04-30 | 2024-04-18 |
| INS19 CAR-T Cells for the Treatment of Relapsed or Refractory Acute B Lymphoblastic Leukemia INS19 CAR-T Cells - Leukemia, B-cell | Phase 1 | Unknown | Beijing Immunochina Medical Science & Technology Co., Ltd. | 12 | 2024-01-15 | 2024-01-17 |
| Safety and Efficacy Evaluation of Next-generation CD19-UCART CD19-UCART - Acute Lymphoblastic Leukemia, Non Hodgkin Lymphoma | Phase 1 | Unknown | Bioray Laboratories | 20 | 2023-12-20 | 2023-01-27 |
| Prospective, Single-arm, Multicenter Clinical Study on Haploidentical Hematopoietic Stem Cell Transplantation in Patients With MRD Positive CD19+ALL Treated With Conditioning Regimens Containing Blinatumomab Blinatumomab - Acute Lymphoblastic Leukemia | Phase 1 | Unknown | Zhejiang University | 31 | 2023-11-16 | 2023-11-09 |
| A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients chidamide, Venetoclax Oral Tablet, Inotuzumab Ozogamicin - Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Unknown | Institute of Hematology & Blood Diseases Hospital, China | 42 | 2023-10-30 | 2023-11-02 |
| A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) . TQB3909 tablet - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 / Phase 2 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 107 | 2023-10-11 | 2023-10-23 |
| Natural Killer(NK) Cell Therapy Targeting CLL1 in Acute Myeloid Leukemia CLL1 CAR-NK cell injection - AML, Adult | Phase 1 | Unknown | Zhejiang University | 24 | 2023-09-10 | 2023-09-07 |
| Clinical Trial Evaluating the Safety of the TQB2928 Injection Combination Therapy TQB2928 Injection + Azacitidine for injection - Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 1 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 48 | 2023-09-01 | 2023-09-06 |
| A Phase 1 Clinical Trail of NTQ2494 Tablets in Patients With Advanced Hematological Malignancies NTQ2494 tablet - Relapsed/Refractory Acute Myeloid Leukemia (AML) | Phase 1 | Unknown | Nanjing Chia-tai Tianqing Pharmaceutical | 72 | 2023-08-07 | 2023-09-22 |
| A Study of TQB3454 Tablets in Patients With Blood Tumors TQB3454 Tablets - Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 1 / Phase 2 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 80 | 2023-07-10 | 2024-01-23 |
| A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies Anti-CD19 Autologous CAR-T Cell Infusion - B-Cell Leukemia, B-Cell Lymphoma | Phase 1 / Phase 2 | Unknown | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | 60 | 2023-07-01 | 2023-07-11 |
| Study of BC3402 in Combination With Azacitidine in Patients With MDS and CMML BC3402, Azacitidine - Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia | Phase 1 | Unknown | Biocity Biopharmaceutics Co., Ltd. | 32 | 2023-06-18 | 2023-08-01 |
| Safety and Efficacy of SMART101 in Adult Patients With Hematological Malignancies After Haploidentical HSCT With Post-transplant Cyclophosphamide Allogeneic T cell progenitors, cultured ex-vivo - Hematological Malignancies | Phase 1 / Phase 2 | Unknown | Smart Immune SAS | 40 | 2023-06-06 | 2023-09-25 |
| CAR T Cells in the Treatment of Refractory and Relapsed CD19+ B Cell Neoplasms FCTX-CL19-1 (Tarcidomgen Kimleucel) - Acute Lymphoblastic Leukemia (ALL), Mantle Cell Lymphoma (MCL) | Phase 1 | Unknown | FamiCordTx | 6 | 2023-05-24 | 2024-09-19 |
| RC1012 Injection (Allo-DNT Cells) for the Prevention of Relapse in AML Patients After Allo-HSCT RC1012 injection (allo-DNT cells) - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Unknown | Guangdong Ruishun Biotech Co., Ltd | 72 | 2023-05-04 | 2023-05-19 |
| A Study on the Efficacy and Safety of Venetoclax Combined With HAA Regimen in Newly Diagnosed Young AML. combination of venetoclax and HAA regimen - Acute Myeloid Leukemia, Venetoclax | Phase 1 / Phase 2 | Unknown | ZePing Zhou | 45 | 2023-04-01 | 2023-06-08 |
| Safety and Efficacy of Venetoclax in Combination With Azacitidine and HA Regimen in the Treatment of AML in the Elderly Venetoclax in Combination With Azacitidine and HA Regimen - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Unknown | ZePing Zhou | 45 | 2023-04-01 | 2023-07-18 |
| Immunotherapy With CD19 CAR T-cells for B-Cell Leukemia Anti-CD19-CAR - Leukemia | Phase 1 | Unknown | Kecellitics Biotech Company Ltd | 100 | 2023-02-01 | 2022-12-01 |
| Umbilical Cord Derived Mesenchymal Stem Cells for Treatment-induced Myelosuppression in Hematologic Malignancies umbilical cord derived mesenchymal stem cells - Hematologic Neoplasms, Neutropenia | Phase 1 / Phase 2 | Unknown | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 181 | 2023-01-01 | 2023-01-05 |
Showing 20 of 271. Sign in to see all of them.
Leukemia, Myeloid, Acute (115) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (69) · Leukemia, Lymphocytic, Chronic, B-Cell (45) · Lymphoma (44) · Recurrence (34) · Myelodysplastic Syndromes (32) · Lymphoma, Non-Hodgkin (27) · Lymphoma, B-Cell (25) · Leukemia, B-Cell (22) · Lymphoma, Large B-Cell, Diffuse (21) · Lymphoma, Mantle-Cell (18) · Lymphoma, Follicular (17) · Burkitt Lymphoma (16) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (14)
Hemic and Lymphatic Diseases (271) · Hematologic Diseases (270) · Neoplasms by Histologic Type (270) · Neoplasms (267) · Immune System Diseases (157) · Immunoproliferative Disorders (156) · Lymphoproliferative Disorders (155) · Lymphatic Diseases (154) · Leukemia, Lymphoid (126) · Leukemia, Myeloid (122) · Pathologic Processes (94) · Pathological Conditions, Signs and Symptoms (94) · Disease Attributes (89) · Lymphoma (59)
Cyclophosphamide (21) · fludarabine (21) · Cytarabine (13) · Immunotherapy, Adoptive (12) · venetoclax (9) · Azacitidine (7) · Sensitivity and Specificity (6) · Antigens, CD19 (5) · Decitabine (5) · Busulfan (4) · Etoposide (4) · fludarabine phosphate (4) · Alemtuzumab (3) · Arsenic Trioxide (3) · Biological Therapy (3)
Chinese PLA General Hospital (10) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (8) · Chongqing Precision Biotech Co., Ltd (7) · PersonGen BioTherapeutics (Suzhou) Co., Ltd. (7) · Hebei Senlang Biotechnology Inc., Ltd. (6) · Southwest Hospital, China (6) · The First Affiliated Hospital of Soochow University (5) · Zhejiang University (5) · iCell Gene Therapeutics (5) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (4) · Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd (4) · The Affiliated Hospital of the Chinese Academy of Military Medical Sciences (4) · Wuhan Sian Medical Technology Co., Ltd (4) · Affiliated Hospital to Academy of Military Medical Sciences (3) · Beijing Doing Biomedical Co., Ltd. (3)
China (149) · United States (41) · France (10) · Germany (10) · Australia (9) · Canada (7) · Italy (7) · Poland (7) · South Korea (6) · United Kingdom (6) · Belgium (5) · Russia (5) · Singapore (4) · Brazil (3) · Israel (3)
Cheng Qian, MD, PhD (6) · Cheng Qian, PhD (6) · Heng Mei, M.D., Ph.D (4) · He Huang, MD (3) · Sanbin Wang, MD (3) · Xiaowen Tang, Ph.D (3) · Gerald L. DeNardo, MD (2) · Heng Mei, M.D. Ph.D (2) · Hongyu Zhang, MD/PhD (2) · Lin Yang, Ph.D. (2) · Olga Aleinikova, MD, Prof (2) · Peihua Lu, MD (2) · Peihua Lu, PhD&MD (2)
PMID 28054442, PMID 34515338, PMID 40195173, PMID 35126471, PMID 35799791, PMID 42826832, PMID 10632319, PMID 15016963, PMID 16564913, PMID 18172005, PMID 18596230, PMID 18616528, PMID 18794884, PMID 20015886, PMID 20371346, PMID 20626398, PMID 20959411, PMID 21791425, PMID 22589701, PMID 23673863, PMID 23876833, PMID 24311149, PMID 24450857, PMID 24450858, PMID 24488563, PMID 24497570, PMID 24615776, PMID 24615777, PMID 24641416, PMID 25174587, PMID 25394714, PMID 25444722, PMID 25621950, PMID 25631767, PMID 25682597, PMID 25805929, PMID 25983002, PMID 26376137, PMID 26497198, PMID 26687796, PMID 26779484, PMID 26819050, PMID 27347147, PMID 27579615, PMID 27716819, PMID 27887660, PMID 27916294, PMID 28039295, PMID 28161329, PMID 28280089
2009 (1), 2014 (1), 2016 (1), 2019 (1), P30CA016672 (1), P30CA060553 (1)